Article
Pharmacogenetic analysis in the treatment of Hodgkin lymphoma.
Leukemia & lymphoma - 1 Aug 2013
Altés Albert, Paré Laia, Esquirol Albert, Xicoy Blanca, Rámila Elena, Vicente Laura, López Rosario, Orriols Jaume, Vall-llovera Ferran, Sánchez-González Blanca, del Río Elisabeth, Sureda Anna, Páez David, Baiget Montserrat
Abstract excerpt
About 15-20% of patients with Hodgkin lymphoma (HL) treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy ± radiotherapy still die following relapse or progressive disease. The outcome might be influenced by gene polymorphisms influencing chemotherapy metabolism. We studied 126 patients with HL treated with the ABVD regimen. We analyzed glutathione S-transferases (GSTT1, GSTM1 and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
